EpiPen: A Quirky Tale of Prescription Drug Pricing

By continuing to use our site you consent to the use of cookies as described in our privacy policy unless you have disabled them.
You can change your cookie settings at any time but parts of our site will not function correctly without them.

Case

Reference no. 317-0011-1

Subject category: Strategy and General Management

Authors: Garima Ratna (Amity Research Centers)

Published by: Amity Research Centers

Published in: 2017

Length: 14 pages

Data source: Published sources

Topics: Epipen; Mylan; Heather Bresch; United States House of Representatives Committee on Oversight and Government Reform; Pricing; Price hike; Generic drug; Auto injectors; Contract manufacturing of drugs; Drug-device

Share a link: https://casecent.re/p/140700

| No reviews for this item

This product has not been used yet

View our pricing guide or login to see prices.

Abstract

In August 2016, Mylan, one of the globally leading pharmaceutical companies had hiked the price of its anti-allergic and life saving drug - EpiPen- to an exorbitant level. This drastic move generated a huge uproar not just among EpiPen users but also amongst the political establishment of the country. The controversy spread to such an extent that Heather Bresch (Bresch), the CEO of Mylan, was summoned by the 'United States House of Representatives Committee on Oversight and Government Reform' for a bipartisan hearing. In her testimony, Bresch justified the price hike and referred to the loopholes in the American pharmaceutical ecosystem. Was Bresch right? Did American pharmaceutical market and the insurance policies need an overhaul? Were there ethical issues related to the hike in life saving drugs and should these ethical issues be swept under the carpet in view of the robust profits these drugs could generate?

Location:

USA

Industry:

Pharmaceutical

Other setting(s):

2016